Neuraminidase is a host‐directed approach to regulate neutrophil responses in sepsis and COVID‐19 (2023)
- Authors:
- USP affiliated authors: CUNHA, FERNANDO DE QUEIROZ - FMRP ; WANDERLEY, CARLOS WAGNER DE SOUZA - FMRP
- Unidade: FMRP
- DOI: 10.1111/bph.16013
- Subjects: COVID-19; LIPOPOLISSACARÍDEOS; METALOPROTEINASES; NEUTRÓFILOS; ESPÉCIES REATIVAS DE OXIGÊNIO; SEPSE
- Keywords: COVID-19; SARS-CoV-2; Metalloproteinase-9; Neuraminidase; Neutrophil; Oseltamivir; Sepsis; Sialic acid; Zanamivir
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: British Journal of Pharmacology
- ISSN: 0007-1188
- Volume/Número/Paginação/Ano: v. 180, n. 11, p.1460-1481, 2023
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
FORMIGA, Rodrigo de Oliveira et al. Neuraminidase is a host‐directed approach to regulate neutrophil responses in sepsis and COVID‐19. British Journal of Pharmacology, v. 180, n. 11, p. 1460-1481, 2023Tradução . . Disponível em: https://doi.org/10.1111/bph.16013. Acesso em: 12 fev. 2026. -
APA
Formiga, R. de O., Amaral, F. C., Souza, C. F., Mendes, D. A. G. B., Wanderley, C. W. de S., Lorenzini, C. B., et al. (2023). Neuraminidase is a host‐directed approach to regulate neutrophil responses in sepsis and COVID‐19. British Journal of Pharmacology, 180( 11), 1460-1481. doi:10.1111/bph.16013 -
NLM
Formiga R de O, Amaral FC, Souza CF, Mendes DAGB, Wanderley CW de S, Lorenzini CB, Santos AA, Antônia J, Faria LF, Natale CC, Paula NM, Cunha F de Q. Neuraminidase is a host‐directed approach to regulate neutrophil responses in sepsis and COVID‐19 [Internet]. British Journal of Pharmacology. 2023 ; 180( 11): 1460-1481.[citado 2026 fev. 12 ] Available from: https://doi.org/10.1111/bph.16013 -
Vancouver
Formiga R de O, Amaral FC, Souza CF, Mendes DAGB, Wanderley CW de S, Lorenzini CB, Santos AA, Antônia J, Faria LF, Natale CC, Paula NM, Cunha F de Q. Neuraminidase is a host‐directed approach to regulate neutrophil responses in sepsis and COVID‐19 [Internet]. British Journal of Pharmacology. 2023 ; 180( 11): 1460-1481.[citado 2026 fev. 12 ] Available from: https://doi.org/10.1111/bph.16013 - Targeting PARP1 to enhance anticancer checkpoint immunotherapy response: rationale and clinical implications
- Glycolytic tumor burden on pretreatment 18F-FDG PET/CT correlates with response and survival in metastatic NSCLC undergoing immune checkpoint inhibitors
- Neuraminidase inhibitors rewire neutrophil function in vivo in murine sepsis and ex vivo in COVID-19
- Nanobodies dismantle post-pyroptotic ASC specks and counteract inflammation in vivo
- Platelets fuel the inflammasome activation of innate immune cells
- Baseline glycolytic tumor burden predicts response and survival in NSCLC and melanoma patients treated with immune checkpoint inhibitors
- Tumor glycolytic profiling through 18F-FDG PET/CT predicts immune checkpoint inhibitor efficacy in advanced NSCLC
- Paradoxical interaction between cancer and long-term postsepsis disorder: impairment of de novo carcinogenesis versus favoring the growth of established tumors
- The role of neutrophils in neuro-immune modulation
- Adjunctive benefits of systemic etoricoxib in non-surgical treatment of aggressive periodontitis: short-term evaluation
Informações sobre o DOI: 10.1111/bph.16013 (Fonte: oaDOI API)
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
003157892.pdf | Direct link |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
